Replies to post #22714 on RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Having seen SP's presentation at JPM (Koestler, one of their VPs did it, it was not inspiring)--I can tell you that the section (admittedly part of a brief overview focused on late stage projects like Saphris/asenapine) on "Ampakine for depression and ADHD" lasted about as long as it took me to type that. Which simply means that, from their view, and the public view, their value drivers are elsewhere, and Org26576 data would not necessarily be material in their opinion.

NeuroInvestment